ArticleDiscover oncology2026
Evaluation of liver function test, kidney function test and hematological profile of gallbladder carcinoma in patients of Eastern Uttar Pradesh region.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of studyThe aim of present study is to assess the change in marker biomolecules of liver, kidney and blood in gall bladder cancer (GBC) patients as compared to age and sex matched healthy individuals. MATERIALS AND
methodsA total of 286 subjects, including 143 histopathologically confirmed GBC patients and 143 age- and sex-unmatched healthy controls, were enrolled in the present study. 3-5 mL of venous blood was withdrawn from histopathologically confirmed GBC patients (before treatment) and control in plain and EDTA vial. Marker enzymes of Liver function test (LFT), Kidney Function Test (KFT), fasting glucose, and hematological indices were assayed using standard clinical chemistry methods. Data analysis was done with Graph Pad Prism 5.02 software, and p < 0.05 was considered significant.
resultsSignificant biochemical changes were observed in the GBC patients as compared to controls. Liver function enzymes such as SGOT (96.77 U/L), SGPT (70.92 U/L), ALP (1041 U/L), and total bilirubin (4.05 mg/dL) were significantly higher in GBC patients, indicating hepatic abnormality (p < 0.0001). The level of urea (36.57 mg/dL) and creatinine (0.98 mg/dL) were also increased significantly as compared to control (p < 0.0004) indicating problem in kidney function. In the patients of GBC, the hemoglobin was low, white blood cell, platelet counts, lymphocytes, monocytes, and eosinophils were significantly high (p < 0.0001) as compared to the healthy control indicating immune system deregulation. Positive correlation between liver enzymes and glucose levels was observed, even more in the older age group of patients (61-80 years), reflecting metabolic stress due to tumor burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.